期刊文献+

胃间质瘤70例临床诊治分析 被引量:12

The Diagnosis and Treatment of Gastric Stromal Tumor:Report of 70 Cases
下载PDF
导出
摘要 目的探讨胃间质瘤的诊治方法及预后。方法对70例经手术治疗的胃间质瘤的临床资料进行回顾性分析。结果行远端胃大部切除术16例,近端胃大部切除术22例,胃楔形切除32例。肿瘤平均直径5.4cm,胃周淋巴结转移2例(2.9%)。免疫组化结果CD117阳性66例(94.3%),CD34阳性53例(75.7%),SMA阳性24例(34.3%),Desmin阳性8例,S100阳性8例。术后复发5例,远处转移6例,术后5年生存率为71.3%。良、恶性胃间质瘤组5年生存率分别为92.3%和61.8%(P<0.05)。瘤体直径<5cm与瘤体直径≥5cm组5年生存率分别为95.0%和48.4%(P<0.05)。结论胃间质瘤的治疗以手术为主,其预后主要与肿瘤大小及肿瘤的良、恶性相关。 Objective:To investigate the diagnosis and treatment of gastric stromal tumors(GSTs).Methods:The clinical data of70cases with GSTs were analyzed retrospectively.Results:Wedge resections were performed on32patients and partial gastrectomies on38patients.The median size of tumors is5.4cm in diameter,2of70(2.9%)had lymph node metastasis.66of70(94.3%)were positive for CD117,53(75.7%)positive for CD34,24positive for SMA,8positive for Desmin and S100.10of70patients recurred or metastasized.The5-year survival rate in this series was71.3%.The5-year survival rate of benign and malignant GSTs were92.3%and61.8%(P<0.05).The5-year survival rate for tumors<5cm and ≥ 5cm were95.0%and48.4%(P<0.05).Conclusions:The primarily treatment of gastric stromal tumor is surgical.Tumor size and mitotic count were found to be important indicators of the prognosis.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2004年第16期934-936,共3页 Chinese Journal of Clinical Oncology
关键词 胃肿瘤 间质瘤 诊断 治疗 Stomach neoplasms Stromal tumors Diagnosis Treatment
  • 相关文献

参考文献10

  • 1[1]Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology[J].Hum Pathol, 1999, 30(10): 1213~1220
  • 2[2]Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science,1998, 279(5350): 577~580
  • 3[3]Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointe-stinal stromal tumours [J]. Lancet Onc, 2002, 3(11): 655~664
  • 4[4]Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571) [J]. Euro J Cancer,2002, 38(sup5): 52~59
  • 5[5]Kim CJ, Day S, Yeh K. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors[J]. Am Surg, 2001, 67(2): 135~138
  • 6[6]DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival[J]. Ann Surg, 2000, 231(1): 51~58
  • 7[7]Matthews BD, Walsh RM, Kercher KW, et al. Laparoscopic vs open resection of gastric stromal tumors[J]. Surg Endosc, 2002, 16(5): 803~807
  • 8[8]Demetri GD, Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].N EnglJ Med, 2002, 347(7): 472~480
  • 9[9]Tmpiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors:A clinicopatho- logic study of 77 cases with nonaggressive and aggressive clinical behaviors [J]. Am J Surg Path, 2002, 26 (6):705~ 714
  • 10[10]Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease[J]. EuroJ Cancer, 2002, 38(sup5): s37~s38

同被引文献123

引证文献12

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部